Rachel Narozniak, MA | Authors

Articles

Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations

March 21, 2020

Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.